The 'pink eye' outbreak has led to a surge in sales of ophthalmology medicine. Sales jumped nearly 30% year-on-year for the second month in a row in August - outgrowing the overall market by almost five times. The rise reflects the massive incidence of conjunctivitis and eye-complications in the last few months across the country.